INOVIO Form 4 — Kim Jong Joseph (Feb. 26, 2022)

Summary

Jong Joseph Kim, Chief Executive Officer and Director of INOVIO PHARMACEUTICALS, INC. [ INO ], reports that 68,767 Restricted Stock Units from a 206,300-unit award vested on 02/26/2022, with 20,045 shares withheld by the issuer at $ 3.22 for taxes. The same day new awards were granted: a Common Stock Option for 627,700 shares at $ 3.22, expiring 02/26/2032, of which 156,925 shares vested on February 26, 2022, and 468,500 Restricted Stock Units vesting 156,167 shares on February 26, 2023, 156,167 on February 26, 2024 and 156,166 on February 26, 2025. Direct holdings end at 1,277,380 shares, with 816,527 listed by a Family Limited Partnership. The form is signed /s/ Jong Joseph Kim, 03/01/2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Kim Jong Joseph (Last) (First) (Middle) 660 W. GERMANTOWN PIKE SUITE 110 (Street) PLYMOUTH MEETING PA 19462 (City) (State) (Zip) | Kim Jong Joseph | (Last) | (First) | (Middle) | 660 W. GERMANTOWN PIKE SUITE 110 | PLYMOUTH MEETING | PA | 19462 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [ INO ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) Chief Executive Officer | X | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | Chief Executive Officer
3. Date of Earliest Transaction
 (Month/Day/Year) 02/26/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 02/26/2022 | M | 68,767 | A | (1) | 1,297,425 | D
Common Stock | 02/26/2022 | F (2) | 20,045 | D | $ 3.22 | 1,277,380 | D
Common Stock | 816,527 | I | By Family Limited Partnership
Common Stock | 33,563 | I | By Daughter: EK
Common Stock | 33,775 | I | By Son: JK1
Common Stock | 5,975 | I | By Spouse
Common Stock | 33,533 | I | By Son: JK2
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Restricted Stock Unit | (1) | 02/26/2022 | M | 68,767 | (1) | (1) | Common Stock | 68,767 | $ 0 (1) | 137,533 | D
Common Stock Option | $ 3.22 | 02/26/2022 | A | 627,700 | 02/26/2022 (3) | 02/26/2032 | Common Stock | 627,700 | $ 0 | 627,700 | D
Restricted Stock Unit | (4) | 02/26/2022 | A | 468,500 | (4) | (4) | Common Stock | 468,500 | $ 0 (4) | 468,500 | D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 206,300 restricted stock units is as follows: 68,767 shares vested on February 26, 2022; 68,767 shares will vest on February 26, 2023; 68,766 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
2. The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein.
3. The vesting schedule for the 627,700 options is as follows: 156,925 shares vested on February 26, 2022; 156,925 shares will vest on February 26, 2023; 156,925 shares will vest on February 26, 2024; 156,925 shares will vest on February 26, 2025.
4. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 468,500 restricted stock units is as follows: 156,167 shares will vest on February 26, 2023; 156,167 shares will vest on February 26, 2024; 156,166 shares will vest on February 26, 2025. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.
Remarks:
/s/ Jong Joseph Kim | 03/01/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_INO_4_filed2022-03-01_0001055726-22-000009.xml

Size

22,492 bytes

SHA-256

81c3f41b7af7b15d473f52e3ecde3d3249d4f70f32d29f2fbb7f124359704f20

Our copy

SEC_INO_4_filed2022-03-01_0001055726-22-000009.xml

Original

www.sec.gov